Signatera Circulating Tumor DNA Test at Chughtai Lab

Signatera Circulating Tumor DNA Test at Chughtai Lab

The Signatera Circulating Tumor DNA (ctDNA) test, outsourced to Natera USA through Chughtai Lab, represents a revolutionary milestone in personalized oncology and molecular diagnostics in Pakistan. Unlike traditional liquid biopsies that utilize a generalized, one-size-fits-all panel to detect common cancer-related mutations, Signatera is a custom-built, tumor-informed assay. It is uniquely designed for each individual patient based on the genomic signature of their own tumor. By identifying and tracking the exact somatic mutations present in the patient’s primary tumor tissue, Signatera provides unprecedented sensitivity and specificity in detecting molecular residual disease (MRD), monitoring treatment response, and identifying early signs of cancer recurrence long before it becomes visible on standard radiological imaging studies.

The underlying technology of Signatera relies on Next-Generation Sequencing (NGS) and advanced multiplex polymerase chain reaction (PCR). Initially, whole-exome sequencing (WES) is performed on the patient’s surgical or biopsy tumor tissue, alongside a matched healthy blood sample, to identify the unique clonal mutations specific to that individual’s cancer. From this genomic profile, Natera designs a personalized assay targeting 16 highly specific, patient-specific somatic mutations. Subsequent blood draws are then analyzed using this customized panel to detect the presence of cell-free tumor DNA circulating in the bloodstream. This tumor-informed approach eliminates the background noise of clonal hematopoiesis of indeterminate potential (CHIP) and other non-tumor genetic variations, ensuring that any detected ctDNA is a highly reliable indicator of active cancer cells remaining in the body.

The clinical importance of this diagnostic tool cannot be overstated. In the adjuvant setting, determining whether a patient has residual microscopic disease after surgical resection is critical for optimizing treatment plans. Patients who test positive for ctDNA post-surgery are at an extremely high risk of recurrence, allowing oncologists to consider more aggressive adjuvant therapies. Conversely, a consistently negative ctDNA result provides reassuring evidence of molecular clearance, potentially sparing patients from the toxicity of unnecessary chemotherapy. Furthermore, during long-term surveillance, Signatera can detect molecular relapse with a median lead time of several months ahead of traditional imaging modalities like CT, MRI, or PET scans, giving clinicians a vital head start in treating recurrent disease when the tumor burden is at its lowest.

Clinical Procedure: What to Expect

Patient Preparation

Because the Signatera ctDNA test is a highly specialized molecular investigation, proper preparation and coordination are essential to ensure accurate results. The preparation process differs significantly from standard blood tests and involves the following critical steps:

• Tissue Sample Acquisition: The primary requirement for the initial Signatera setup is the acquisition of the patient’s formalin-fixed paraffin-embedded (FFPE) tumor tissue block or freshly cut unstained slides from a previous surgical resection or biopsy. Chughtai Lab coordinates the collection of this tissue block from the pathology archive where the biopsy was originally processed.
• Matched Normal Sample: A baseline blood sample is collected alongside the tissue sample to sequence the patient’s normal DNA, allowing the laboratory to filter out inherited (germline) genetic variations and focus solely on tumor-specific somatic mutations.
• No Fasting Required: For the subsequent longitudinal blood draws, no fasting or special dietary restrictions are required. Patients can eat, drink, and take their regular medications as prescribed.
• Clinical Documentation: Patients must provide comprehensive clinical records, including the original histopathology report, previous oncology treatment history, current staging, and a signed consent form for international genetic testing.
• Scheduling: It is critical to schedule the post-surgical blood draw at an appropriate clinical window—typically at least 2 to 4 weeks post-surgery—to avoid false-positive ctDNA elevations caused by transient cell-free DNA released during surgical tissue trauma.

During the Procedure

The blood collection procedure for the Signatera test is straightforward, minimally invasive, and conducted under strict quality control protocols at Chughtai Lab centers across Pakistan:

• Venipuncture: A trained phlebotomist performs a standard venipuncture to collect blood from a vein in the patient’s arm.
• Specialized Collection Tubes: The blood is drawn into specialized tubes (typically Streck tubes) containing proprietary preservatives that stabilize nucleated blood cells, preventing them from lysing and diluting the circulating tumor DNA with healthy genomic DNA during transit.
• Strict Labeling and Verification: The sample is labeled with unique identifiers, matching the patient’s personalized assay profile registered with Natera USA.
• Cold Chain Logistics: Once collected, Chughtai Lab processes and packages the specimen according to strict international shipping guidelines. The sample is maintained at controlled ambient temperatures to preserve DNA integrity during transit to Natera’s CAP-accredited and CLIA-certified laboratory in the United States.
• Safety and Comfort: The blood draw takes less than 10 minutes, carries minimal risk of bruising or localized discomfort, and allows the patient to resume normal daily activities immediately.

When is a Signatera Circulating Tumor DNA Test Performed?

Molecular Residual Disease (MRD) Assessment after Surgery

Following the surgical removal of a primary solid tumor, such as in colorectal, breast, lung, or bladder cancer, clinicians must determine if the surgical resection was curative or if microscopic cancer cells remain. Signatera is performed in this post-operative window to detect molecular residual disease (MRD). Identifying residual ctDNA at this stage indicates that micrometastases are still present in the body, providing a clear clinical indication that adjuvant systemic therapy may be required to prevent clinical recurrence.

Early Detection of Cancer Recurrence during Surveillance

For patients in clinical remission, routine surveillance is vital to detect cancer recurrence at the earliest possible stage. Signatera is performed at regular intervals (e.g., every 3 to 6 months) during the surveillance phase. Because ctDNA can detect molecular relapse months before tumors grow large enough to be visualized on CT or PET scans, this test provides oncologists with an early warning system, enabling therapeutic intervention when the disease burden is minimal and potentially more treatable.

Monitoring Response to Adjuvant Chemotherapy

During or immediately following adjuvant chemotherapy, Signatera is utilized to evaluate the effectiveness of the treatment. A declining trend or complete clearance of ctDNA during chemotherapy indicates that the tumor cells are highly sensitive to the selected drugs. Conversely, persistent or rising ctDNA levels suggest treatment resistance, prompting oncologists to re-evaluate the therapeutic regimen, consider alternative agents, or enroll the patient in clinical trials.

Evaluating Immunotherapy Treatment Efficacy

In advanced or metastatic cancer patients receiving immune checkpoint inhibitors, traditional imaging can sometimes show a temporary increase in tumor size known as “pseudoprogression,” which is caused by immune cell infiltration rather than actual tumor growth. Signatera is performed to differentiate pseudoprogression from true disease progression. A decrease in ctDNA levels confirms a positive response to immunotherapy, preventing the premature discontinuation of an effective treatment.

Long-term Surveillance for High-Risk Solid Tumors

Patients diagnosed with high-risk solid tumors, including stage II-III colorectal cancer, muscle-invasive bladder cancer, and high-risk breast cancer, face a significant risk of late recurrence. Signatera is integrated into long-term surveillance protocols for these patients. By providing highly specific molecular surveillance, the test helps clinicians customize follow-up schedules, offering peace of mind to patients with consistently negative results while maintaining high vigilance for those with detectable ctDNA.

What Does a Signatera Circulating Tumor DNA Test Detect?

The Signatera ctDNA test is designed to detect and quantify minute amounts of tumor-derived DNA in the bloodstream. It provides highly specific clinical findings, including:

• Presence of Molecular Residual Disease (MRD): Detects microscopic residual tumor cells remaining in the body after curative-intent surgery.
• Molecular Relapse: Identifies the re-emergence of tumor DNA in the blood during the surveillance phase, indicating cancer recurrence.
• Quantifiable Mutant Allele Fraction (MAF): Measures the proportion of mutated tumor DNA relative to the total cell-free DNA in the sample, reflecting tumor burden.
• ctDNA Clearance: Confirms the complete disappearance of detectable tumor DNA following successful surgical resection or systemic therapy.
• ctDNA Persistence: Detects the ongoing presence of tumor-specific mutations despite therapeutic interventions, indicating residual active disease.
• Dynamic ctDNA Fluctuations: Tracks rising or falling trends in ctDNA levels across multiple sequential blood draws to assess real-time treatment response.
• Therapeutic Resistance: Identifies a lack of ctDNA reduction during active chemotherapy or targeted therapy, suggesting tumor resistance.
• Early Response to Immunotherapy: Detects rapid decreases in ctDNA levels within weeks of initiating immunotherapy, correlating with long-term clinical benefit.
• Molecular Progression: Detects a significant increase in ctDNA concentration, indicating disease progression before radiographic evidence appears.
• Tumor-Informed Somatic Mutations: Specifically tracks up to 16 clonal mutations unique to the patient’s primary tumor genomic profile.
• Absence of Clonal Hematopoiesis Interference: Filters out non-tumor mutations associated with aging blood cells, ensuring high diagnostic specificity.
• Systemic Tumor Burden Correlation: Reflects the overall volume of active, shedding tumor cells present throughout the body.

Turnaround Time and Report Access at Chughtai Lab

The turnaround time for the Signatera ctDNA test involves two distinct phases due to its highly personalized, tumor-informed nature. The initial setup phase, which requires sequencing the patient’s primary tumor tissue block and matched normal blood sample to design the custom 16-mutation assay, typically takes approximately 3 to 4 weeks from the time the tissue sample is received at the Natera laboratory in the USA. Once this personalized assay is successfully designed and established, subsequent longitudinal monitoring blood tests have a significantly shorter turnaround time, usually taking about 10 to 14 days from the blood draw at Chughtai Lab.

Chughtai Lab ensures a seamless and professional reporting process for patients across Pakistan. Once the highly detailed molecular report is finalized by Natera’s clinical genomics experts, it is securely transmitted to Chughtai Lab’s advanced laboratory information management system. Patients and their referring oncologists can easily access the comprehensive reports online through the official Chughtai Lab website or via the user-friendly Chughtai Lab mobile application. Additionally, printed copies of the reports can be collected from any main diagnostic center, and patients receive automated SMS notifications as soon as their results are ready for download.

Signatera Findings Overview

The following table outlines the clinical interpretation of various parameters evaluated during a Signatera ctDNA test:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
ctDNA Status (MRD Assessment)	Negative (Undetectable ctDNA)	Positive (Detectable ctDNA, indicating residual microscopic disease)
Mean Tumor Molecules (MTM/mL)	0.0 MTM/mL (No tumor molecules detected per milliliter of plasma)	>0.0 MTM/mL (Quantifiable tumor DNA, indicating active tumor burden)
Longitudinal ctDNA Trend	Consistently Undetectable	Rising MTM/mL levels over sequential draws (suggesting disease progression or recurrence)
Post-Surgical Clearance	ctDNA becomes undetectable within 2-4 weeks post-resection	Persistent ctDNA post-surgery (indicating incomplete resection or micrometastases)
Therapy Response (Chemotherapy)	Significant decline or complete clearance of ctDNA during treatment	Stable or increasing ctDNA levels (suggesting treatment resistance)
Immunotherapy Response	Rapid decrease in ctDNA levels within early cycles of therapy	Rising ctDNA levels (confirming true disease progression rather than pseudoprogression)
Surveillance Monitoring	Undetectable ctDNA throughout the surveillance period	Detection of ctDNA (molecular relapse) prior to clinical or radiological recurrence

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Signatera Circulating Tumor DNA Test?

• Experienced Healthcare Professionals: Chughtai Lab features a highly trained team of molecular pathologists, technologists, and clinical coordinators specialized in advanced genomic diagnostics.
• Patient-Focused Care: Dedicated support staff guide patients through the complex process of tissue acquisition, consent documentation, and sample tracking.
• Quality Diagnostic Services: Chughtai Lab maintains stringent quality control standards, ensuring the integrity of samples from collection to international shipment.
• Professional Reporting: Seamless integration with Natera USA ensures that patients receive highly detailed, accurate, and clinically actionable molecular reports.
• Modern Diagnostic Approach: By offering cutting-edge liquid biopsy tests like Signatera, Chughtai Lab brings world-class personalized oncology monitoring to Pakistan.
• Comfortable Environment: State-of-the-art collection centers across Pakistan provide a comfortable, professional, and hygienic environment for specialized blood draws.
• Convenient Location: With an extensive nationwide network of diagnostic centers, patients can easily access blood draw services in major cities including Lahore, Karachi, and Islamabad.
• Commitment to Accurate Diagnosis: Chughtai Lab’s robust cold chain logistics preserve the delicate cell-free DNA in patient samples during long-distance international transit to Natera’s US facilities.